Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Hangzhou Jointech Raises $62 Million for Orthopedic Surgery Robots

publication date: Jun 25, 2021

Jointech, a Hangzhou medical device company, has raised $62 million over the last 15 months to support its orthopedic surgery robot business. The latest funding, a C round worth at least $32 million, was led by Lyfe Capital. The company's surgical robot for total hip replacement is under China special review for innovative medical instruments and is expected to become the first domestic joint replacement surgical robot approved in China. Jointech is also developing a knee replacement robot and other surgical robots. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital